Szpital Ruber Internacional
Typical Leiomyosarkoma Treatment Costs in Spain
Bookimed Expert Insight: Patients with complex or rare sarcoma types benefit most from multidisciplinary teams at JCI-accredited centers. Centro Médico Teknon offers high-tier oncology care and robotized surgeries, having served high-profile international figures. For those seeking innovative protocols, Quironsalud Madrid provides unique value through clinical trials that may offer free treatment for eligible participants. Pediatric cases require specialized centers like SJD Barcelona Children’s Hospital, which ranks among Europe's top three pediatric facilities.
| Turcja | Austria | Hiszpania | |
| Zogniskowana ablacja ultradźwiękowa (HIFU) | od $4,000 | od $12,000 | od $6,000 |
| Terapia protonowa w raku prostaty | od $30,000 | od $80,000 | od $70,000 |
| Terapia protonowa przy raku piersi | od $30,000 | od $55,000 | od $85,000 |
| Terapia protonowa | od $70,000 | od $80,000 | od $25,352 |
| Radioterapia raka odbytnicy | od $7,000 | od $12,000 | od $10,000 |
Posiadając ponad 20-letnie doświadczenie w onkologii dziecięcej, dr Lopez Ibor kieruje Oddziałem Hematologii i Onkologii Dziecięcej w szpitalu HM Montepríncipe.
Lekarz jest wybitnym onkologiem medycznym z ponad 30-letnim doświadczeniem, specjalizującym się w niechirurgicznym leczeniu nowotworów układu moczowo-płciowego, w tym raka prostaty, nerek i pęcherza moczowego, a także mięsaków i guzów o nieznanym pochodzeniu. Obecnie lekarz kieruje Oddziałem Nowotworów Układu Moczowo-Płciowego, Centralnego Układu Nerwowego, Mięsaków i Guzów o Nieznanym Pochodzeniu w Szpitalu Uniwersyteckim Vall d'Hebron w Barcelonie i współpracuje z Centrum Medycznym Teknon.<\/p>
Posiadając doktorat z medycyny i chirurgii, lekarz prowadził liczne krajowe wieloośrodkowe badania kliniczne i jest autorem ponad 120 recenzowanych artykułów. Lekarz jest uznawany za jednego z czołowych ekspertów w Hiszpanii w dziedzinie onkologii układu moczowo-płciowego.<\/p>
Spain features designated CSUR national reference centers and private JCI-accredited clinics specializing in leiomyosarcoma care. Key institutions include Vall d Hebron and Quironsalud, which provide multidisciplinary teams. These centers utilize advanced technologies like Proteus One proton therapy for complex soft-tissue and retroperitoneal cases.
Bookimed Expert Insight: While public referral centers are vital, private centers like Quironsalud Madrid offer unique access to clinical trials for neurodegenerative and oncological disorders. Their proton therapy packages, priced between $22,000 and $65,000, provide specialized abdominal and sarcoma protocols often unavailable at standard oncology units. This specialized focus is critical as leiomyosarcoma requires precision radiation to protect surrounding organs.
Patient Consensus: Patients emphasize finding dedicated sarcoma tumor boards rather than general oncology units to avoid mismanagement. They strongly recommend getting a second pathology review and confirming the surgeon has specific experience with soft-tissue sarcomas.
Spanish oncology teams utilize multidisciplinary tumor boards at specialized reference centers to design leiomyosarcoma plans. These panels follow Spanish Group for Research in Sarcomas guidelines. Decisions integrate precise histological staging with surgical resectability. This centralized approach ensures patients receive expertise from high-volume sarcoma units.
Bookimed Expert Insight: Spanish centers like Proton Therapy Centre Quironsalud are diversifying specialized care. They offer Proteus One technology for complex re-irradiations and pediatric cases. This is significant because leiomyosarcoma often requires precise radiation when surgical margins are narrow. Our data shows these specialized centers manage over 900 cases. This volume suggests a higher level of technical proficiency than general hospitals.
Patient Consensus: Patients emphasize that a precise pathology review at a high-volume center can change the entire treatment plan. They note it is important to have all imaging and reports ready for second opinions if surgery is not offered initially.
Localized resectable leiomyosarcoma in Spain is primarily treated through wide en bloc surgical resection with negative margins. This curative approach is managed within the national Centros, Servicios y Unidades de Referencia network. Guidelines favor multidisciplinary planning and selective use of advanced radiation techniques.
Bookimed Expert Insight: Spanish oncology centers offer a significant advantage through high-volume specialization. Hospital Universitario HM Madrid manages over 2.3 million outpatients annually. This massive patient flow allows multidisciplinary teams to develop rare expertise in leiomyosarcoma. Patients should look for centers that integrate specialized units like the Baselga Institute of Oncology at Hospital Quiron Barcelona. These institutions often provide access to clinical trials that are not available at general hospitals.
Patient Consensus: Patients emphasize the importance of seeking care at high-volume sarcoma units rather than general surgery departments. They note that expert pathology review is essential before surgery to ensure the diagnosis is accurate.
Advanced radiation modalities for deep-seated leiomyosarcoma include Proton Therapy using Proteus ONE and Stereotactic Body Radiation Therapy. These techniques deliver high doses to unreachable tumors while protecting nearby organs. Spanish JCI-accredited centers also utilize Brachytherapy and Intraoperative Radiation Therapy for cases with difficult margins.
Bookimed Expert Insight: While many facilities offer standard radiotherapy, Spain features specialized centers like Proton Therapy Centre Quironsalud, the first of its kind in the country. Data shows these centers offer highly specific protocols, such as cancer re-radiation packages for patients who have already reached their traditional radiation limits. Choosing a center with MGH Boston-trained specialists like Dr. Carme Ares ensures access to the same precision standards used in leading American institutions.
Patient Consensus: Patients emphasize the need for a multidisciplinary team to determine if radiation is for local control or tumor shrinkage. Many recommend verifying a clinic's experience specifically with deep-seated soft-tissue sarcomas to ensure effective planning.
Spain offers a comprehensive range of systemic and targeted therapies for leiomyosarcoma. Standard options include Doxorubicin as first-line chemotherapy and Trabectedin for subsequent care. Target-specific treatments like Pazopanib are available at JCI-accredited centers such as Centro Médico Teknon or Quironsalud Madrid.
Bookimed Expert Insight: Spain’s oncology network allows for high specialization in rare sarcomas. JCI-accredited facilities like Centro Médico Teknon serve 10,000 patients annually. Large networks like Quironsalud offer clinical trial participation for free. This access provides patients with emerging DNA-repair inhibitors and personalized immunotherapy protocols.
Patient Consensus: Patients note that Doxorubicin is the standard starting point for metastatic cases. They emphasize the importance of seeking a sarcoma multidisciplinary team for second opinions.
Patients receiving leiomyosarcoma treatment in Spain can join clinical trials through coordinated research networks like GEIS. Eligibility depends on specific tumor markers and wash-out periods from current therapies. Leading JCI-accredited centers in Madrid and Barcelona actively recruit for advanced oncology studies while providing standard care.
Bookimed Expert Insight: Spain ranks 6th globally in our medical network, reflecting a high concentration of research-led oncology centers. Data shows that clinics like Hospital Universitario HM Madrid and Quironsalud are major hubs for complex cases. These institutions often integrate trials into standard treatment plans. Patients should discuss enrollment before starting new therapy lines to avoid eligibility conflicts.
Patient Consensus: Patients emphasize the need for tumor molecular testing to unlock more trial options. They also note that stopping current treatment for a three-week washout period is a common requirement.